Natdac
Tenofovir Disoproxil · Daclatasvir · Sofosbuvir
Indicated to manage hepatitis c to mitigate viral infection.
- Categories
- HIV Management · Antivirals
- Active ingredients
- Tenofovir Disoproxil · Daclatasvir · Sofosbuvir
- Supply
- Rx
- Route
- Oral use
- Form
- Tablet
- Strengths
- 60mg
Natdac details
- Condition
- Chronic Hepatitis C
- Alternative names
- Epclusa
- Therapeutic class
- Direct-Acting Antiviral
- Pharmacological class
- HCV Protease/Polymerase Inhibitor
- Contraindications
- hypersensitivity to active components
- Minor side effects
- fatigue; headache; nausea
- Moderate side effects
- insomnia; dizziness; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Patient summary
- indicated to manage hepatitis c to mitigate viral infection.
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Natco Pharma
- Onset Time
- 1–2 weeks
- Duration
- 12–24 weeks
- Storage instructions
- Store in original packaging.
- Drug interactions
- amiodarone; rifampicin; st. john's wort
- Age restrictions
- For adults.
- Pregnancy and breastfeeding
- Pregnancy: Not recommended. Breastfeeding: Not recommended.
Precautions and warnings
monitor for hepatitis b reactivation; frequent monitoring of liver function; no alcohol consumption
Serious side effects
hepatitis b reactivation, requires immediate medical attention; severe bradycardia, requires immediate medical attention
Mechanism of action
This combination therapy targets the HCV NS5A and NS5B proteins, inhibiting viral replication through multiple pathways. This multi-target approach is essential for achieving a sustained virological response.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Natdac
Natdac is a combined therapy containing Tenofovir Disoproxil, Daclatasvir and Sofosbuvir, frequently used for the management of Chronic Hepatitis C. This combination acts as a generic alternative to the brand Epclusa. Produced by Natco Pharma, the medication is supplied as a tablet in 60mg strength.
Natdac availability in Asia
Natdac is registered across five markets including Indonesia, Thailand and Malaysia, with availability also in the Philippines. Generic medicine produced in India often offers a more affordable alternative to the original brand for patients living far from well stocked city pharmacies. This therapy is intended for use under the guidance of a doctor to ensure appropriate care.